modelAcetylsalicylicAcidAndCo
Extends from Pharmacolibrary.Drugs.ATC.M.M01BA03.
Information
| name: | AcetylsalicylicAcidAndCorticosteroids | |
| ATC code: | M01BA03 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 10 | L |
| clearance: | 15 | L/h |
| other parameters in model implementation | ||
Acetylsalicylic acid (aspirin) and corticosteroids is a fixed drug combination classified under ATC code M01BA03, primarily used for its anti-inflammatory, analgesic, and antipyretic effects. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and corticosteroids suppress immune response and inflammation. Such combinations have been used in various inflammatory conditions such as rheumatoid arthritis. Fixed combinations of aspirin and corticosteroids are rarely used in current clinical practice due to the risk of gastrointestinal toxicity and more effective therapies being available.
Pharmacokinetics
Estimated pharmacokinetic parameters for an average healthy adult following oral administration, based on known PK of acetylsalicylic acid and common corticosteroids (such as prednisolone); no direct publication with population PK modeling data for the fixed combination.
References
Hayashi, H, et al., & Taniguchi, M (2020). Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial. American journal of respiratory and critical care medicine 201(12) 1488–1498. DOI:10.1164/rccm.201906-1215OC PUBMED:https://pubmed.ncbi.nlm.nih.gov/32142372
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)